奥美罗斯制药
OMER
16.20
-2.59
-13.78%
奥美罗斯制药
US · OMER
#3062 按市值排名
上市于 1970
16.20
-2.59
-13.78%
实时 - 追踪5344个代码 - 心跳于336秒前
· 2026-10-16 19:49
✦ 量化股权信号 计算方式说明
减持
- 最近一期（2026/Q3）披露持股的机构数量减少了1家。
- 机构持股总比例下降了0.8个百分点。
机构持股
- 机构持股比例
- 49.98% -0.76pp
- 机构数量
- 195 -1
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向一致机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund42.87%
Individual/Insider4.29%
Hedge Fund4.23%
Public Company1.31%
Private Company0.86%
Government Pension Fund0.32%
Insurance Company0.17%
Family Office/Trust0.13%
Other45.73%
主要股东 截至 2026-06-30
BlackRock
8.35% · 6.04M 股
Ingalls & Snyder, LLC
5.06% · 3.66M 股
Vanguard Capital Management, LLC
4.92% · 3.56M 股
UBS Asset Management
4.42% · 3.20M 股
State Street Global Advisors
3.20% · 2.32M 股
Geode Capital Management, LLC
2.64% · 1.91M 股
Stifel Asset Management Corp.
2.54% · 1.84M 股
Gregory Demopulos
2.03% · 1.47M 股
Peter Demopulos
1.34% · 972.90K 股
Vanguard Portfolio Management, LLC
1.33% · 962.83K 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 36次买入 · 11次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Gregory Demopulos | Chairperson & CEO | 2.03% |
| Peter Demopulos | Director | 1.34% |
| Joseph Schocken | Director | 0.73% |
| Leroy Hood | Independent Director | 0.10% |
| Thomas Cable | Lead Independent Director | 0.05% |
| Arnold Hanish | Independent Director | 0.02% |
| Thomas Bumol | Independent Director | 0.01% |
| Peter Cancelmo | General Counsel | 0.00% |
| Rajiv Shah | Independent Director | -- |
| Diana Perkinson | Independent Director | -- |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-22 | David Borges | VP of Finance, Chief Accounting Officer & Treasurer | Derivative Exercise and Sale | -20,000 | $2.94–20.95 |
| 2026-08-30 | Peter Cancelmo | General Counsel | Derivative Exercise and Sale | -50,000 | $2.94–18.65 |
| 2026-08-26 | Arnold Hanish | Independent Director | Derivative Exercise and Sale | -15,000 | $14.66–19.02 |
| 2026-08-23 | David Borges | VP of Finance, Chief Accounting Officer & Treasurer | Derivative Exercise and Sale | -10,906 | $2.94–19.10 |
| 2026-08-19 | Thomas Cable | Lead Independent Director | Derivative Exercise and Sale | -15,000 | $2.00–18.45 |
| 2026-08-12 | David Borges | VP of Finance, Chief Accounting Officer & Treasurer | Derivative Exercise and Sale | -5,000 | $3.93–16.95 |
| 2026-08-11 | Joseph Schocken | Director | Other Derivative Acquisition | +30,000 | $13.71 |
| 2026-08-11 | Joseph Schocken | Director | Initial Statement of Beneficial | 0 | -- |
| 2026-07-21 | Gregory Demopulos | Chairperson & CEO | Other Derivative Acquisition | +1,000,000 | $9.84 |
| 2026-07-21 | Peter Cancelmo | General Counsel | Other Derivative Acquisition | +105,000 | $9.84 |
| 2026-07-21 | David Borges | VP of Finance, Chief Accounting Officer & Treasurer | Other Derivative Acquisition | +105,000 | $9.84 |
| 2026-06-17 | Thomas Cable | Lead Independent Director | Other Derivative Acquisition | +15,000 | $10.28 |
| 2026-06-17 | Leroy Hood | Independent Director | Other Derivative Acquisition | +15,000 | $10.28 |
| 2026-06-17 | Arnold Hanish | Independent Director | Other Derivative Acquisition | +15,000 | $10.28 |
| 2026-06-17 | Peter Demopulos | Director | Other Derivative Acquisition | +15,000 | $10.28 |
| 2026-06-17 | Thomas Bumol | Independent Director | Other Derivative Acquisition | +15,000 | $10.28 |
| 2026-06-17 | Rajiv Shah | Independent Director | Other Derivative Acquisition | +15,000 | $10.28 |
| 2026-06-17 | Diana Perkinson | Independent Director | Other Derivative Acquisition | +15,000 | $10.28 |
| 2026-05-21 | Thomas Cable | Lead Independent Director | Derivative Exercise and Sale | -7,500 | $10.84–11.61 |
| 2026-02-17 | Gregory Demopulos | Chairperson & CEO | Derivative Exercise and Sale | -357,678 | $10.27–11.93 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:49:38 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
奥美罗斯制药 讨论区 0 条评论